Provided by Tiger Trade Technology Pte. Ltd.

AdvisorShares Psychedelics ETF

25.12
+0.35181.42%
Post-market: 25.120.00000.00%16:10 EDT
Volume:36.09K
Turnover:911.60K
Market Cap:58.28M
PE:- -
High:25.49
Open:24.86
Low:24.74
Close:24.77
52wk High:27.02
52wk Low:15.63
Shares:2.32M
Float Shares:2.32M
Volume Ratio:0.86
T/O Rate:1.56%
Dividend:1.70
Dividend Rate:6.79%
ROE:--
ROA:--
PB:--
PE(LYR):- -

Loading ...

Compass Pathways to Report Q2, First-half Results, Host Conference Call

Reuters
·
Jul 29

Compass Pathways to Announce Second Quarter and First Half 2026 Financial Results on August 5, 2026

THOMSON REUTERS
·
Jul 29

Microba Raises $5.4m Through Placement and SPP Ahead of FY26 Results

TIPRANKS
·
Jul 29

Alkermes Plc : Jefferies Raises Target Price to $72 from $65

THOMSON REUTERS
·
Jul 29

Alkermes Plc : TD Cowen Raises Target Price to $58 from $57

THOMSON REUTERS
·
Jul 29

Alkermes Plc : Baird Raises Target Price to $58 from $48

THOMSON REUTERS
·
Jul 29

Lakes Blue Energy Highlights Exploration Risks in Capital Raising Brief

TIPRANKS
·
Jul 29

Lakes Blue Energy launches $8.7m capital raising and reshapes board

TIPRANKS
·
Jul 29

Acrow shareholders back capital raisings at extraordinary meeting

TIPRANKS
·
Jul 29

Vita Resources Ends Oakley Capital Mandate as It Resets Funding Strategy

TIPRANKS
·
Jul 29

Wall Street Analysts Are Bullish on Top Healthcare Picks

TIPRANKS
·
Jul 29

Alkermes Price Target Raised to $65.00/Share from $43.00 by Piper Sandler

Dow Jones
·
Jul 29

Analysts’ Opinions Are Mixed on These Healthcare Stocks: Alkermes (ALKS) and Universal Health (UHS)

TIPRANKS
·
Jul 28

Alkermes Plc Reports Results for the Quarter Ended June 30 - Earnings Summary

Reuters
·
Jul 28

Alkermes Releases Transcript of Q2 2026 Earnings Call

Reuters
·
Jul 28

Alkermes sinks 5% to $50.05 following Q2 report

TIPRANKS
·
Jul 28

Relmada Therapeutics Names Bipin Dalmia Chief Business Officer

Reuters
·
Jul 28

Relmada Therapeutics Appoints Uro-Oncology Leader Bipin Dalmia as Chief Business Officer

THOMSON REUTERS
·
Jul 28

Alkermes Q2 Earnings Flat, Revenue Rises; Reiterates 2026 Revenue Guidance

MT Newswires Live
·
Jul 28

Atea Pharmaceuticals reports C-BEYOND trial meets primary, secondary endpoints

TIPRANKS
·
Jul 28